164 related articles for article (PubMed ID: 18505122)
1. [Application of caffeine-halothane contracture test in the diagnosis of malignant hyperthermia].
Wang YL; Guo XY; Xu ZH; Huang YG; Luo AL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Apr; 30(2):182-6. PubMed ID: 18505122
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
4. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
5. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
[TBL] [Abstract][Full Text] [Related]
6. Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility.
Johannsen S; Klingler W; Schneiderbanger D; Heiderich S; Roewer N; Schuster F
Acta Anaesthesiol Scand; 2013 Oct; 57(9):1161-6. PubMed ID: 23957432
[TBL] [Abstract][Full Text] [Related]
7. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Bina S; Cowan G; Karaian J; Muldoon S; Mongan P; Bünger R
Anesthesiology; 2006 Jan; 104(1):90-100. PubMed ID: 16394695
[TBL] [Abstract][Full Text] [Related]
8. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
[TBL] [Abstract][Full Text] [Related]
9. Malignant hyperthermia suggestive hypermetabolic syndrome at emergence from anesthesia.
Christiaens F; Gepts E; D'Haese J; Camu F
Acta Anaesthesiol Belg; 1995; 46(2):93-7. PubMed ID: 8714856
[TBL] [Abstract][Full Text] [Related]
10. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and diagnosis for Chinese cases with malignant hyperthermia: a case cluster from 2005 to 2007.
Wang YL; Luo AL; Tan G; Cui XL; Guo XY
Chin Med J (Engl); 2010 May; 123(10):1241-5. PubMed ID: 20529573
[TBL] [Abstract][Full Text] [Related]
12. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
[TBL] [Abstract][Full Text] [Related]
13. Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene.
Matos AR; Sambuughin N; Rumjanek FD; Amoedo ND; Cunha LB; Zapata-Sudo G; Sudo RT
Braz J Med Biol Res; 2009 Dec; 42(12):1218-24. PubMed ID: 19918671
[TBL] [Abstract][Full Text] [Related]
14. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
[TBL] [Abstract][Full Text] [Related]
16. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
[TBL] [Abstract][Full Text] [Related]
17. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
18. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
Britt BA; Scott EA
Anesth Analg; 1986 Feb; 65(2):171-5. PubMed ID: 3942305
[TBL] [Abstract][Full Text] [Related]
19. Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript.
Loke JC; Kraev N; Sharma P; Du G; Patel L; Kraev A; MacLennan DH
Anesthesiology; 2003 Aug; 99(2):297-302. PubMed ID: 12883402
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
Wehner M; Rueffert H; Koenig F; Olthoff D
Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
